MAPT and early-onset autosomal dominant Alzheimer disease: demonstrate that the DPP4-i saxagliptin reduces beta-amyloid, tau accumulation (main culprits of neurodegeneration) and inflammatory markers and increases hippocampal GLP-1 and memory retention in mouse models of Alzheimer’s disease.